Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant SARS-CoV-2 XBB.1.5 variant vaccine
- Development stage
- Unknown
- Lead developer
- PLA General Hospital Seventh Medical Center
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The recombinant SARS-CoV-2 XBB.1.5 variant vaccine is a protein subunit vaccine developed by the Seventh Medical Center of the PLA General Hospital. It is specifically designed to target the XBB.1.5 subvariant of the SARS-CoV-2 Omicron lineage, which is characterized by significant immune evasion. The vaccine is produced using the Sf9 insect cell expression system, which allows for the production of recombinant Spike proteins that mimic the viral structure to elicit a robust immune response. It is intended for the prevention of COVID-19 and is administered via intramuscular injection. Clinical trials (Phase 1/2) have been initiated to evaluate its safety, tolerability, and immunogenicity in healthy adults.
- Other names
- recombinant SARS-CoV-2 XBB.1.5 variant vaccine (Sf9 Cells)
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on recombinant SARS-CoV-2 XBB.1.5 variant vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant SARS-CoV-2 XBB.1.5 variant vaccine.